Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.100
+0.150 (3.80%)
Oct 9, 2026, 10:58 AM EDT - Market open
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 600 employees as of December 31, 2025. The number of employees decreased by 200 or -25.00% compared to the previous year. That makes Recursion Pharmaceuticals the 18,720th largest employer in the world and 2,554th in the United States.
Employees
600
Change (1Y)
-200
Growth (1Y)
-25.00%
Revenue / Employee
$91,427
Profits / Employee
-$864,807
Market Cap
2.20B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -200 | -25.00% |
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Beam Therapeutics | 540 |
| Vera Therapeutics | 361 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Immunome | 247 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 165 |
RXRX News
- 1 day ago - Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today - TheFly
- 3 days ago - Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today - TheFly
- 18 days ago - Tempus AI, Recursion extend data license agreement, enter new license agreement - TheFly
- 18 days ago - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model - Business Wire
- 24 days ago - Recursion Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley - TheFly
- 1 month ago - Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference - Transcripts
- 2 months ago - Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts